Figure 1. Mesothelioma mortality in The Netherlands 1997–2002 (source: Netherlands National Institute of Statistics). From: Occupational asbestos exposure:

Slides:

Advertisements

Similar presentations

FROM EUROCHIP-1 TO EUROCHIP-2 EUROCHIP-2 - The action Public Health Program EUROPEAN COMMISSION: HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL.

Advertisements

Impact on histo-pathological reporting with different specimen collection protocols for TRUS biopsy of the prostate. F Harris, C Fragkopoulou, V Dabbagh,

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

Medical aspects of asbestos exposure Sjaak Burgers respiratory physician Netherlands Cancer Institute, Amsterdam

Laboratory Careers Packet #4. Introduction Individuals working in this field have various tasks, duties, interests and abilities. Laboratory personnel.

April 2014 Dr J King Dr K Syred.  90% mesotheliomas are linked to asbestos exposure  May be eligible for compensation  3 yr survival rate 8%  Subtype.

FIGURES Chapter 5, Instructor’s Manual. © 2006 by John R. Griffith and Kenneth R. White FIGURE 5.1 Decision Tree for Evaluating Surgical Treatment for.

Figure 2. Quality of life (QOL) scores for functional scale items

Figure 1. FinHER dataset: distribution of tumor-infiltrating lymphocytes in breast cancer according to the (A) three breast cancer subtypes and (B) HER2.

Figure 1. Dose modification scheme for the second cycle of capecitabine treatment. From: Adjuvant capecitabine chemotherapy using a tailored-dose strategy.

Figure 1. Raw mean scores of the MFI subscales ‘mental fatigue’ and ‘reduction in motivation’ (range 4–20, the higher the score the more mental fatigue.

From: Asbestos and Smoking as Risk Factors for Idiopathic Retroperitoneal FibrosisA Case–Control Study Ann Intern Med. 2014;161(3): doi: /M

Figure 1. (A) Forest plot of common odds ratios (adjusted for ECOG PS) for best overall response by a priori subgroups in patients with KRAS wild-type.

Figure 1 (A) Chest computed tomography scans of the patient

Figure 2. (A) Sézary syndrome patient before treatment

Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center Raja M. Flores, MD, Maureen Zakowski, MD, Ennapadam.

Figure 3. Sensitivity of the gastric carcinoma cell line N87 for trastuzumab in comparison with the breast cancer cell line SKBR-3. (A) Dose–response curves.

Figure 3. Visualisation of ESMO-MCB scores for curative and non-curative setting. A & B and 5 and 4 represent the grades with substantial improvement.

Figure 1. Dosage and administration route of drugs used in the BMD study. Each cycle was proposed every 28 days (‘base’ schedule) or 35 days (‘weekly’

Figure 1. (A) Cumulative risk of breast (diamonds) and ovarian (squares) cancer in BRCA1 mutation carriers. (B) Cumulative risk of breast (diamonds) and.

Figure 1. Trial profile. From: Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer Ann Oncol. 2006;17(4): doi: /annonc/mdl001.

Figure 1. Progression-free survival and overall survival for FL/DLBCL patients. From: Clinicobiological features and prognostic impact of diffuse large.

Epidemiology of Environmental Exposure and Malignant Mesothelioma

Ran Zhuo, Brendon D. Parsons, Bonita E. Lee, Steven J

Figure 1. Patterns of HER2–PET/CT confronted with FDG–PET/CT, Maximum intensity projection. Lesion uptake was considered pertinent when visually higher.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

Approach to diagnosis of infective endocarditis

Epidemiology of Environmental Exposure and Malignant Mesothelioma

Peripheral Arterial Disease: Diagnosis and Management

Lung Cancer Screening. The Pulmonologist’s Role in Improving Personalized Diagnosis and Treatment of NSCLC.

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

A 5-Year Prospective Observational Study of the Outcomes of International Treatment Guidelines for Crohn's Disease Garret Cullen, Denise Keegan, Hugh.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

(A) Frequency of synchronous diagnosis of primary tumour and BM according to primary tumour type (B) Frequency of patients with asymptomatic BM at first.

Field evaluation of a second-generation cytometer UF-100 in diagnosis of acute urinary tract infections in adult patients F. Manoni, S. Valverde, F.

The added value of hepatitis E diagnostics in determining causes of hepatitis in routine diagnostic settings in the Netherlands M.H.E. Doting, J. Weel,

Flow chart of the used methodology adapted from Moher et al

Detection rate for EGFR mutations in cfDNA.

The Molecular Pathology of Primary Immunodeficiencies

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Figure 1. Bar plots of age-standardized (world population) death rates per 100 000 persons for the year 2014 (blue, ... Figure 1. Bar plots of age-standardized.

PRISMA study flow diagram

Histological and molecular heterogeneity of triple negative breast cancer (TNBC). Histological and molecular heterogeneity of triple negative breast cancer (TNBC).

Patients represented by 441 physicians surveyed from 19 countries, depicted in the patient journey from diagnosis to ensuing treatment with ADT. ADT, androgen.

(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.

Jeffrey T. Yorio, MD, Yang Xie, PhD, Jingsheng Yan, PhD, David E

Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled.

Figure 1. Survival curves from a hypothesized clinical trial randomizing patient to standard of care with and without ... Figure 1. Survival curves from.

European guidelines for diagnosis and management of patients with suspected herpes simplex encephalitis Miles Denton, Kevin G Kerr, Fraser Lewis Clinical.

Elizabeth Mileti, Philip Rosenthal, Marion G. Peters

Figure 1. Relationships among microsatellite instability (MSI; letter A indicates the group with MSI), high tumour ... Figure 1. Relationships among microsatellite.

Prognostic Factors in the Treatment of Malignant Pleural Mesothelioma at a Large Tertiary Referral Center Raja M. Flores, MD, Maureen Zakowski, MD, Ennapadam.

Figure 6 Schematic diagram of the CAT system

Patients’ most feared AEs reported to be intolerable when lasting more than 7 days at baseline, on study and at study completion (% patients); (A) grade.

Figure 1. Oncoprint of selected pathogenic alterations detected in ctDNA. Unless provided in the caption above, the following copyright applies to the.

Postmortem Mesothelioma Diagnosis

Alport syndrome: Is diagnosis only skin-deep?

Figure 1. Radiographic and gross pathologic measurements of ‘tumor mass’ include areas of immune-mediated tumor ... Figure 1. Radiographic and gross pathologic.

Figure 2. Biomarkers for prediction of differences in PFS and objective response rate between GP and GT arm in patients ... Figure 2. Biomarkers for prediction.

Concentration-time profiles of repeated weekly infusions of (A) 720 mg and (B) 990 mg tomuzotuximab measured in individual patients before and at the end.

Figure 1. Sequential programmed death-ligand-1 (PD-(L)1) blockade and osimertinib schema of patients who developed ... Figure 1. Sequential programmed.

Outcome and prognostic factors of pleural mesothelioma after surgical diagnosis and/or pleurodesis Mariette Baud, MD, Salvatore Strano, MD, PhD, Agnes.

On the left, Euler-Venn diagram of point mutations detected by lbNGS and ttNGS on matched genes from the same patients; on the right, the percentage of.

The 22 study patients: overall survival (first patient enrolled 9 May 2014, last patient enrolled 26 August 2015, censoring date 9 May 2016); primary tumour.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Figure 1. CONSORT diagram.

• Kaplan-Meier analyses of (A) time-to-recurrence (TTR) for the subgroup of patients with high-risk melanoma who had relapsed (n=82), (B) recurrence-free.

Kaplan–Meier analysis of PFS and OS in patients with advanced non-small cell lung cancer with adenocarcinoma histology with time since start of first-line.

Figure 1. Forest plot of lung cancer mortality in LDCT trials.

Cumulative amounts in 5-year periods from 1946 to 2010 of import of raw asbestos to Norway (data from Statistics Norway ( 2002), incidence.

Presentation transcript:

Figure 1. Mesothelioma mortality in The Netherlands 1997–2002 (source: Netherlands National Institute of Statistics). From: Occupational asbestos exposure: how to deal with suspected mesothelioma cases—the Dutch approach Ann Oncol. 2006;17(5):848-852. doi:10.1093/annonc/mdl021 Ann Oncol | © 2006 European Society for Medical Oncology

Figure 2. Flow diagram of the protocol Figure 2. Flow diagram of the protocol. Patients first present their case to the IAV (Institute for Asbestos Victims) who collect data and pathology specimen which are sent to the NMP (Netherlands Mesothelioma Panel) for pathologic evaluation. When no diagnosis can be made based on the available histological or cytological specimen all available data are sent to the Mesothelioma Group (MG). From: Occupational asbestos exposure: how to deal with suspected mesothelioma cases—the Dutch approach Ann Oncol. 2006;17(5):848-852. doi:10.1093/annonc/mdl021 Ann Oncol | © 2006 European Society for Medical Oncology